Role of adhesion molecules determined by immunohistochemical assays in the prediction of lymph node involvement and prognosis of endometrial carcinomas

• Grant number: 18/06717-8
• Support Opportunities: Regular Research Grants
• Start date: November 01, 2018
• End date: October 31, 2020
• Field of knowledge: Health Sciences - Medicine - Pathological Anatomy and Clinical Pathology
• Principal Investigator: Filomena Marino Carvalho
• Grantee: Filomena Marino Carvalho
• Host Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Associated researchers: Jesus Paula Carvalho

Abstract

Endometrial carcinomas occur more frequently in the endometrioid histological type, until then considered the prototype of the estrogen-related carcinomas (type I), often diagnosed still restricted to the uterine body and considered of favorable prognosis. The increasing incidence along with the advances in the molecular knowledge exposed their heterogeneity and the need for different therapeutic approaches. There are some recurrence risk classifications based on classic features such as surgical staging, type and histologic grade, patient age, tumor size, and vascular involvement. The possibility of less invasive surgical procedures and more precise indications of the various forms of adjuvant therapy still require a better characterization of the aggressive potential of these neoplasms. In this scenario, we propose to evaluate the role of the immunohistochemical expression of L1CAM, e-cadherin and catenin-beta adhesion molecules in endometrial carcinomas in the risk of lymph node involvement and prognosis. We selected patients with endometrial carcinoma submitted to surgical staging according to FIGO criteria and extracted from the medical records and pathological reports: age, body mass index, preoperative serum CA125 value, date of diagnosis, date and type of adverse events, date of the last follow-up, tumor size, tumor location in the uterine cavity and number of lymph nodes. The slides will be reviewed for histological typing and grading, level and type of myometrial infiltration, presence and extent of vascular involvement and selection of representative areas of the tumor to construct tissue microarrays blocks and determination of the immunohistochemical profile. The following markers will be performed: estrogen receptor (ER), progesterone receptor (PR), p53, p16, catenin-beta, MLH1, MSH2, MSH6, PMS2, e-cadherin and L1CAM. All variables will be tested for their association with risk categories, lymph node involvement and prognosis determined by overall survival, recurrence-free survival, and adverse events. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

DE FREITAS, DANIELA; AGUIAR, FERNANDO NALESSO; ANTON, CRISTINA; DE ALMEIDA, DANIELLE CRISTINA; BACCHI, CARLOS EDUARDO; CARVALHO, JESUS PAULA; CARVALHO, FILOMENA MARINO. Clinicopathological characteristics of endometrial carcinomas according to DNA mismatch repair protein status. HELIYON, v. 9, n. 6, p. 11-pg., 2023-06-01. (18/06717-8)

DE FREITAS, DANIELA; AGUIAR, FERNANDO NALESSO; ANTON, CRISTINA; BACCHI, CARLOS EDUARDO; CARVALHO, JESUS PAULA; CARVALHO, FILOMENA MARINO. L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion. PLoS One, v. 13, n. 12, DEC 17 2018. (18/06717-8)